Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".

Ching-Yi Chen Guo-Sheng Wang James Cheng-Chung Wei

J Thorac Oncol

Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Nursing, Chung Shan Medical University, Taichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. Electronic address:

Published: May 2024

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jtho.2024.02.007	DOI Listing

Publication Analysis

Top Keywords

comment "consolidation

"consolidation osimertinib

osimertinib versus

versus durvalumab

durvalumab concurrent

concurrent chemoradiation

chemoradiation unresectable

unresectable egfr-mutant

egfr-mutant nsclc"

comment

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!